This research develops “nanozymes,” nanoparticle-based catalysts that activate cancer drugs directly at tumor sites. Instead of carrying large amounts of chemotherapy drugs, nanozymes locally trigger inactive drugs into their active form only within cancer tissue. Early mouse studies show effective tumor destruction with significantly reduced side effects compared to conventional chemotherapy.

Chronic diseases exhaust the body’s CD8 T cells, weakening their ability to fight infections and cancer. This research identifies CD7 as a key driver of T-cell exhaustion. Removing CD7 keeps T cells active, boosts cytokine production, and improves control of tumors and viruses—offering a promising new immunotherapy target.